Lung cancer has emerged as a major global public health concern. With growing public interest in lung cancer, online searches for related information have surged. However, a comprehensive evaluation of the credibility, quality, and value of lung cancer-related videos on digital media platforms remain...
The present invention relates to a kit for estimating a survival period of a lung cancer patient using composite mutant epidermal growth factor receptor (EGFR), and to a method for providing information for estimating the survival period, enabling detection of composite mutant EGFR deeply associated ...
"The goal of identifying these genetic signatures in lung cancer is not just to determine how long a cancer patient will live, but also to home in on the most relevant drug or therapy targets that act specifically on these particular gene products," said Dr. Mangelsdorf, who also is an i...
Development and validation of a nomogram based on common biochemical indicators for survival prediction of children with high-risk neuroblastoma: A valuable tool for resource-limited hospitals. January 26, 2023 [ MEDLINE Abstract ] [ Full-text from Publisher's Site ] Factors associated with in...
However, the immunophenotypic profile of MHC class I and TAP-1 seems to be unrelated in vivo to the phenotype, growth or survival of NSCLC.P... P,Korkolopoulou,L,... - 《British Journal of Cancer》 被引量: 253发表: 1996年 Implications of life-history transitions on the population gene...
The 5-year overall survival rates were 71% for XELODA and 68% for fluorouracil + leucovorin. Table 10 Efficacy Results in X-ACT* (All Randomized Population) Efficacy ParametersXELODA(N=1004)Fluorouracil + Leucovorin(N=983) * Approximately 93.4% had 5-year DFS information † Based on ...
Statistical information (e.g., on long-term survival or side effects) may be valuable for healthcare providers to share with their patients to facilitate shared decision making on treatment options. In this pre-registered study, we assessed cancer surviv
Efficacy was established based on event-free survival (EFS), where an event was defined as occurrence of progressive disease, relapse, second malignancy, death from any cause, or non-response as evidenced by detection of viable cells in residue after the second CYVE course, whichever occurs firs...
Acancer registryis an information system where comprehensive data on cancer patients is in a standardized manner to support statistical analysis and answer questions related to trends in particular types of cancer, e.g., changes in the incidence or survival rates (Bieh-Zimmert et al., 2013). C...
TECENTRIQ, as a single-agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA [see Clinical Studies (14.1)] non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determ...